Daily non-political popular news in brief.
A drug's brand name skews patient treatment choices
05-21-2007 · EurekAlert!The brand name of a drug can strongly influence treatment decisions by patients, according to a randomized trial of decision aids by researchers from McMaster University.
Read more »
Keywords: drug, brand, name, skews, patient, treatment, choices, skew, choice
« Previous | Next »
Similar news on "A drug's brand name skews patient treatment choices":
- Cost control measures limit patient and physician choice in psychotropic medications
03-01-2007 · EurekAlert!
A new Brandeis University study published online in Clinical Therapeutics suggests that private health plans increasingly rely on escalating copayments to manage drug costs, as opposed to administrative controls. This makes treatment more expensive in many cases for patients, and may affect adherence to treatment, said lead author Dominic Hodgkin, associate professor at the Schneider Institute for Behavioral Health, Heller School for Social Policy and Management at Brandeis University.
Similar news · Read more »
- Men with prostate cancer avoid radiation due to misconceptions
11-05-2006 · EurekAlert!
Negative perceptions about radiation therapy can strongly influence a prostate cancer patient's choice to avoid external beam radiation therapy, even though studies have proven the treatment to be as safe and effective as other treatments for the disease, including surgery, according to a study presented November 5, 2006, at the American Society for Therapeutic Radiology and Oncology's 48th Annual Meeting in Philadelphia.
Similar news · Read more »
- DNA Highly Promising Predictor For Successful Treatment Of Alcoholics
10-05-2006 · ScienceDaily
According to Dutch researcher Wendy Ooteman, the biological and genetic characteristics of alcoholics can predict which drugs will best suppress the desire to drink. Naltrexone and acamprosate are drugs that are supposed to suppress the desire for a drink. The researcher investigated which patient characteristics were responsible for predicting the drug that would work best.
Similar news · Read more »
- Benefit of exenatide has not yet been proven
10-17-2007 · EurekAlert!
Since May 2007, a new drug has been available for the treatment of patients with diabetes mellitus type 2 in Germany: exenatide (trade name: Byetta), which is marketed by the manufacturer Eli Lilly. According to current evidence, the blood-glucose lowering effect of exenatide has been demonstrated, but is not superior to the corresponding effect of insulin. Moreover, there is no evidence to show that the improved glycaemic control contributes to a reduction in the rate of late complications of diabetes.
Similar news · Read more »
- Israeli scientists identify: Genes that affect responses of multiple sclerosis patients to copaxone
10-10-2007 · EurekAlert!
Getting the drug dosage correct can be a tricky exercise in trial and error in a disease like multiple sclerosis. Scientists from the Weizmann Institute and the Technion have identified two genes that affect a patient's response to the drug Copaxone, a finding which may help take the some of the guesswork out of treatment.
Similar news · Read more »
- St. Jude finds anti-leukemia drug increases patient fatigue
11-01-2007 · EurekAlert!
The anti-leukemia drug dexamethasone contributes to a relentless fatigue and poor quality of sleep in children undergoing treatment for acute lymphoblastic leukemia, according to a new study from St. Jude Children's Research Hospital. The finding suggests that clinicians could improve the quality of life for these children by developing new methods of drug administration that reduce or eliminate these side effects.
Similar news · Read more »
- Patients can't recall their medications to tell doctors
10-11-2007 · EurekAlert!
Doctors depend on patients to accurately tell them what drugs they are taking in out-patient visits. But Northwestern University found nearly 50 percent of patients taking antihypertensive drugs were unable to accurately name a single one of their medications. Thus, doctors can't monitor if a drug is working or know about potential adverse interactions.
Similar news · Read more »
- Gene therapy for erectile dysfunction shows promise in clinical trial
12-01-2006 · EurekAlert!
The first human trial of gene transfer therapy for erectile dysfunction (ED) indicates that gene therapy that lasts for months and eliminates the patient's need for on-demand drugs (such as Viagra and Cialis), could become the future treatment of choice for this common problem, according to a paper in the most recent issue of Human Gene Therapy.
Similar news · Read more »
- 'Mismatched' prostate cancer treatment more common than expected
11-26-2007 · EurekAlert!
More than a third of men with early prostate cancer who participated in a study analyzing treatment choice received therapies that might not be appropriate, based on pre-existing problems with urinary, bowel or sexual function. The prevalence of these treatment "mismatches" could reflect patient unwillingness to discuss such problems with their physicians.
Similar news · Read more »
- Memantine and Alzheimer's disease
01-10-2008 · EurekAlert!
In a study published in the Journal of Alzheimer's Disease, researchers from the University of Aberdeen report that the drug memantine, used for the treatment of Alzheimer's disease and praised as "the first and only representative of a new class of Alzheimer drugs" works in fact similar to other existing compounds, and is beneficial only in a narrow concentration range. They further indicate that the complex pharmacological profile of memantine requires careful consideration concerning suitable doses and suitable patient groups.
Similar news · Read more »
